APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urological Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Urological Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025190 pages

Choose your research edition.

Industry ResearchUrological Cancer Drugs Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Urological Cancer Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Urological Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urological Cancer Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Urological Cancer Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Urological Cancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Urological Cancer Drugs include Johnson & Johnson, Novartis, Pfizer, GlaxoSmithKline, AstraZeneca, Tolmar Inc, Sanofi S.A, Roche Healthcare and Ipsen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urological Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urological Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urological Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urological Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Urological Cancer Drugs Segment by Company

Johnson & Johnson

Novartis

Pfizer

GlaxoSmithKline

AstraZeneca

Tolmar Inc

Sanofi S.A

Roche Healthcare

Ipsen

Indevus Pharmaceuticals Inc

Ferring Pharmaceuticals

Dendreon Corporation

Celgene Corporation

Bristol-Myers Squibb

Astellas

Abbott Laboratories

Urological Cancer Drugs Segment by Type

Tablets

Injection

Urological Cancer Drugs Segment by Application

Bladder Cancer

Testicular Cancer

Prostate Cancer

Kidney Cancer

Others

Urological Cancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urological Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urological Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urological Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urological Cancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Urological Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Urological Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Urological Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Urological Cancer Drugs Industry Trends Table 2. Urological Cancer Drugs Industry Drivers Table 3. Urological Cancer Drugs Industry Opportunities and Challenges Table 4. Urological Cancer Drugs Industry Restraints Table 5. Global Urological Cancer Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Urological Cancer Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Urological Cancer Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Urological Cancer Drugs Sales Market Share by Manufacturers Table 9. Global Urological Cancer Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Urological Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Urological Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Urological Cancer Drugs Manufacturers, Product Type & Application Table 13. Global Urological Cancer Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Urological Cancer Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tablets Table 17. Major Manufacturers of Injection Table 18. Global Urological Cancer Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Urological Cancer Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Urological Cancer Drugs Sales Market Share by Type (2021-2026) Table 22. Global Urological Cancer Drugs Sales Market Share by Type (2027-2032) Table 23. Global Urological Cancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Urological Cancer Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Urological Cancer Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Urological Cancer Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Urological Cancer Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Bladder Cancer Table 29. Major Manufacturers of Testicular Cancer Table 30. Major Manufacturers of Prostate Cancer Table 31. Major Manufacturers of Kidney Cancer Table 32. Major Manufacturers of Others Table 33. Global Urological Cancer Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 35. Global Urological Cancer Drugs Sales by Application (2027-2032) & (K Units) Table 36. Global Urological Cancer Drugs Sales Market Share by Application (2021-2026) Table 37. Global Urological Cancer Drugs Sales Market Share by Application (2027-2032) Table 38. Global Urological Cancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Urological Cancer Drugs Revenue by Application (2021-2026) & (K Units) Table 40. Global Urological Cancer Drugs Revenue by Application (2027-2032) & (K Units) Table 41. Global Urological Cancer Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Urological Cancer Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Urological Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Urological Cancer Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Urological Cancer Drugs Sales Market Share by Region (2021-2026) Table 46. Global Urological Cancer Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Urological Cancer Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Urological Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 50. North America Urological Cancer Drugs Sales by Country (2027-2032) & (K Units) Table 51. Europe Urological Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 53. Europe Urological Cancer Drugs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Urological Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Urological Cancer Drugs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Urological Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Urological Cancer Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Urological Cancer Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Urological Cancer Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Urological Cancer Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Urological Cancer Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Urological Cancer Drugs Revenue Market Share by Region (2027-2032) Table 65. Johnson & Johnson Company Information Table 66. Johnson & Johnson Business Overview Table 67. Johnson & Johnson Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Johnson & Johnson Urological Cancer Drugs Product Portfolio Table 69. Johnson & Johnson Recent Development Table 70. Novartis Company Information Table 71. Novartis Business Overview Table 72. Novartis Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Novartis Urological Cancer Drugs Product Portfolio Table 74. Novartis Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pfizer Urological Cancer Drugs Product Portfolio Table 79. Pfizer Recent Development Table 80. GlaxoSmithKline Company Information Table 81. GlaxoSmithKline Business Overview Table 82. GlaxoSmithKline Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. GlaxoSmithKline Urological Cancer Drugs Product Portfolio Table 84. GlaxoSmithKline Recent Development Table 85. AstraZeneca Company Information Table 86. AstraZeneca Business Overview Table 87. AstraZeneca Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. AstraZeneca Urological Cancer Drugs Product Portfolio Table 89. AstraZeneca Recent Development Table 90. Tolmar Inc Company Information Table 91. Tolmar Inc Business Overview Table 92. Tolmar Inc Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Tolmar Inc Urological Cancer Drugs Product Portfolio Table 94. Tolmar Inc Recent Development Table 95. Sanofi S.A Company Information Table 96. Sanofi S.A Business Overview Table 97. Sanofi S.A Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Sanofi S.A Urological Cancer Drugs Product Portfolio Table 99. Sanofi S.A Recent Development Table 100. Roche Healthcare Company Information Table 101. Roche Healthcare Business Overview Table 102. Roche Healthcare Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Roche Healthcare Urological Cancer Drugs Product Portfolio Table 104. Roche Healthcare Recent Development Table 105. Ipsen Company Information Table 106. Ipsen Business Overview Table 107. Ipsen Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Ipsen Urological Cancer Drugs Product Portfolio Table 109. Ipsen Recent Development Table 110. Indevus Pharmaceuticals Inc Company Information Table 111. Indevus Pharmaceuticals Inc Business Overview Table 112. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio Table 114. Indevus Pharmaceuticals Inc Recent Development Table 115. Ferring Pharmaceuticals Company Information Table 116. Ferring Pharmaceuticals Business Overview Table 117. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio Table 119. Ferring Pharmaceuticals Recent Development Table 120. Dendreon Corporation Company Information Table 121. Dendreon Corporation Business Overview Table 122. Dendreon Corporation Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Dendreon Corporation Urological Cancer Drugs Product Portfolio Table 124. Dendreon Corporation Recent Development Table 125. Celgene Corporation Company Information Table 126. Celgene Corporation Business Overview Table 127. Celgene Corporation Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Celgene Corporation Urological Cancer Drugs Product Portfolio Table 129. Celgene Corporation Recent Development Table 130. Bristol-Myers Squibb Company Information Table 131. Bristol-Myers Squibb Business Overview Table 132. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio Table 134. Bristol-Myers Squibb Recent Development Table 135. Astellas Company Information Table 136. Astellas Business Overview Table 137. Astellas Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Astellas Urological Cancer Drugs Product Portfolio Table 139. Astellas Recent Development Table 140. Abbott Laboratories Company Information Table 141. Abbott Laboratories Business Overview Table 142. Abbott Laboratories Urological Cancer Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Abbott Laboratories Urological Cancer Drugs Product Portfolio Table 144. Abbott Laboratories Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. Urological Cancer Drugs Distributors List Table 148. Urological Cancer Drugs Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Urological Cancer Drugs Product Image Figure 2. Global Urological Cancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urological Cancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Urological Cancer Drugs Sales (2021-2032) & (K Units) Figure 5. Global Urological Cancer Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Urological Cancer Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tablets Image Figure 9. Injection Image Figure 10. Global Urological Cancer Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Urological Cancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Urological Cancer Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Urological Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Urological Cancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Urological Cancer Drugs Revenue Market Share by Type (2021-2032) Figure 16. Bladder Cancer Image Figure 17. Testicular Cancer Image Figure 18. Prostate Cancer Image Figure 19. Kidney Cancer Image Figure 20. Others Image Figure 21. Global Urological Cancer Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Urological Cancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Urological Cancer Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Urological Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Urological Cancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Urological Cancer Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Urological Cancer Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Urological Cancer Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Urological Cancer Drugs Sales Market Share by Country (2021-2032) Figure 41. China Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Urological Cancer Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Urological Cancer Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Urological Cancer Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Urological Cancer Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Urological Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Urological Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Urological Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Urological Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Urological Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Urological Cancer Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Urological Cancer Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Injection
Applications
  • Bladder Cancer
  • Testicular Cancer
  • Prostate Cancer
  • Kidney Cancer
  • Others
Companies covered
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Tolmar Inc
  • Sanofi S.A
  • Roche Healthcare
  • Ipsen
  • Indevus Pharmaceuticals Inc
  • Ferring Pharmaceuticals
  • Dendreon Corporation
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Astellas
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Urological Cancer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Urological Cancer Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Urological Cancer Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Urological Cancer Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Urological Cancer Drugs Market Dynamics
  1. 2.1 Urological Cancer Drugs Industry Trends
  2. 2.2 Urological Cancer Drugs Industry Drivers
  3. 2.3 Urological Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Urological Cancer Drugs Industry Restraints
3 Urological Cancer Drugs Market by Manufacturers
  1. 3.1 Global Urological Cancer Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Urological Cancer Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Urological Cancer Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Urological Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Urological Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Urological Cancer Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Urological Cancer Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Urological Cancer Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Urological Cancer Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Urological Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Urological Cancer Drugs Market by Type
  1. 4.1 Urological Cancer Drugs Type Introduction
  2. 4.1.1 Tablets
  3. 4.1.2 Injection
  4. 4.2 Global Urological Cancer Drugs Sales by Type
  5. 4.2.1 Global Urological Cancer Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Urological Cancer Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Urological Cancer Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Urological Cancer Drugs Revenue by Type
  9. 4.3.1 Global Urological Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Urological Cancer Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Urological Cancer Drugs Revenue Market Share by Type (2021-2032)
5 Urological Cancer Drugs Market by Application
  1. 5.1 Urological Cancer Drugs Application Introduction
  2. 5.1.1 Bladder Cancer
  3. 5.1.2 Testicular Cancer
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Kidney Cancer
  6. 5.1.5 Others
  7. 5.2 Global Urological Cancer Drugs Sales by Application
  8. 5.2.1 Global Urological Cancer Drugs Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Urological Cancer Drugs Sales by Application (2021-2032)
  10. 5.2.3 Global Urological Cancer Drugs Sales Market Share by Application (2021-2032)
  11. 5.3 Global Urological Cancer Drugs Revenue by Application
  12. 5.3.1 Global Urological Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Urological Cancer Drugs Revenue by Application (2021-2032)
  14. 5.3.3 Global Urological Cancer Drugs Revenue Market Share by Application (2021-2032)
6 Global Urological Cancer Drugs Sales by Region
  1. 6.1 Global Urological Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urological Cancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Urological Cancer Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Urological Cancer Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Urological Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Urological Cancer Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Urological Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Urological Cancer Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Urological Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Urological Cancer Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Urological Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Urological Cancer Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Urological Cancer Drugs Revenue by Region
  1. 7.1 Global Urological Cancer Drugs Revenue by Region
  2. 7.1.1 Global Urological Cancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Urological Cancer Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Urological Cancer Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Urological Cancer Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Urological Cancer Drugs Revenue (2021-2032)
  8. 7.2.2 North America Urological Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Urological Cancer Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Urological Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Urological Cancer Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Urological Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Urological Cancer Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Urological Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Urological Cancer Drugs Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Urological Cancer Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Urological Cancer Drugs Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Urological Cancer Drugs Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Urological Cancer Drugs Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Tolmar Inc
  32. 8.6.1 Tolmar Inc Company Information
  33. 8.6.2 Tolmar Inc Business Overview
  34. 8.6.3 Tolmar Inc Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Tolmar Inc Urological Cancer Drugs Product Portfolio
  36. 8.6.5 Tolmar Inc Recent Developments
  37. 8.7 Sanofi S.A
  38. 8.7.1 Sanofi S.A Company Information
  39. 8.7.2 Sanofi S.A Business Overview
  40. 8.7.3 Sanofi S.A Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi S.A Urological Cancer Drugs Product Portfolio
  42. 8.7.5 Sanofi S.A Recent Developments
  43. 8.8 Roche Healthcare
  44. 8.8.1 Roche Healthcare Company Information
  45. 8.8.2 Roche Healthcare Business Overview
  46. 8.8.3 Roche Healthcare Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Roche Healthcare Urological Cancer Drugs Product Portfolio
  48. 8.8.5 Roche Healthcare Recent Developments
  49. 8.9 Ipsen
  50. 8.9.1 Ipsen Company Information
  51. 8.9.2 Ipsen Business Overview
  52. 8.9.3 Ipsen Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ipsen Urological Cancer Drugs Product Portfolio
  54. 8.9.5 Ipsen Recent Developments
  55. 8.10 Indevus Pharmaceuticals Inc
  56. 8.10.1 Indevus Pharmaceuticals Inc Company Information
  57. 8.10.2 Indevus Pharmaceuticals Inc Business Overview
  58. 8.10.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio
  60. 8.10.5 Indevus Pharmaceuticals Inc Recent Developments
  61. 8.11 Ferring Pharmaceuticals
  62. 8.11.1 Ferring Pharmaceuticals Company Information
  63. 8.11.2 Ferring Pharmaceuticals Business Overview
  64. 8.11.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio
  66. 8.11.5 Ferring Pharmaceuticals Recent Developments
  67. 8.12 Dendreon Corporation
  68. 8.12.1 Dendreon Corporation Company Information
  69. 8.12.2 Dendreon Corporation Business Overview
  70. 8.12.3 Dendreon Corporation Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Dendreon Corporation Urological Cancer Drugs Product Portfolio
  72. 8.12.5 Dendreon Corporation Recent Developments
  73. 8.13 Celgene Corporation
  74. 8.13.1 Celgene Corporation Company Information
  75. 8.13.2 Celgene Corporation Business Overview
  76. 8.13.3 Celgene Corporation Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Corporation Urological Cancer Drugs Product Portfolio
  78. 8.13.5 Celgene Corporation Recent Developments
  79. 8.14 Bristol-Myers Squibb
  80. 8.14.1 Bristol-Myers Squibb Company Information
  81. 8.14.2 Bristol-Myers Squibb Business Overview
  82. 8.14.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio
  84. 8.14.5 Bristol-Myers Squibb Recent Developments
  85. 8.15 Astellas
  86. 8.15.1 Astellas Company Information
  87. 8.15.2 Astellas Business Overview
  88. 8.15.3 Astellas Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Urological Cancer Drugs Product Portfolio
  90. 8.15.5 Astellas Recent Developments
  91. 8.16 Abbott Laboratories
  92. 8.16.1 Abbott Laboratories Company Information
  93. 8.16.2 Abbott Laboratories Business Overview
  94. 8.16.3 Abbott Laboratories Urological Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Abbott Laboratories Urological Cancer Drugs Product Portfolio
  96. 8.16.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urological Cancer Drugs Value Chain Analysis
  2. 9.1.1 Urological Cancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urological Cancer Drugs Production Mode & Process
  6. 9.2 Urological Cancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urological Cancer Drugs Distributors
  9. 9.2.3 Urological Cancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst